Close
Help




JOURNAL

Clinical Medicine Insights: Endocrinology and Diabetes

120,660 Journal Article Views | Journal Analytics

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Submit a Paper



Publication Date: 12 Jan 2011

Type: Review

Journal: Clinical Medicine Insights: Endocrinology and Diabetes

Citation: Clinical Medicine Insights: Endocrinology and Diabetes 2011:4 1-12

doi: 10.4137/CMED.S5114

Abstract

The prevalence of type 2 diabetes mellitus is high and growing rapidly. Suboptimal glycemic control provides opportunities for new treatment options to improve the morbidity and mortality of this progressive disease. Saxagliptin, a selective DPP-4 inhibitor, increases endogenous incretin levels and incretin acitivty. In controlled clinical trials saxagliptin reduces both fasting and postprandial glucose and works in monotherapy and in combination with metformin, TZDs and sulfonylureas. Saxagliptin has a very favourable side effect profile and may have other beneficial non-glycemic effects. The authors review the current available evidence for the safety, efficacy and saxagliptin's place in therapy for type 2 diabetes mellitus. As understanding of the incretin hormones (GLP-1, GIP) expand we may see additional important non-glycemic effects that may affect the chronic management of type 2 diabetes mellitus.


Downloads

PDF  (582.32 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML






What Your Colleagues Say About Clinical Medicine Insights: Endocrinology and Diabetes
My experience with Libertas Academica was excellent. The review process was smooth and speedy. After publishing, I received a kind and favorable response from a reader. I have never experienced such a comment after my publications to orthodox journals.
Dr Hiro Koshiyama (Kitano Hospital, Osaka, Japan, and Kyoto University, Kyoto, Japan)
More Testimonials

Quick Links


New article and journal news notification services